Ash 2020 preview – early winners and losers
Unveiling of abstracts for December’s haematology meeting sent Crispr up and Allogene down, but the biggest beneficiary was private.
Another complement factor enters the deal-making frame
Sobi picking up rights to Apellis’s complement factor C3 inhibitor adds to earlier deals focused on C5, D and anti-FcRn antibodies.
Key biotech catalysts approach
Important clinical data are expected in the fourth quarter from biotech companies including Madrigal, Arena, Rhythm and Forma.
Are the stars waning for Pfizer’s haemophilia A gene therapy?
Could Pfizer/Sangamo’s project be facing the same durability issues as Biomarin’s Roctavian?
Disaster strikes for Akebia
Cardiac safety threatens to derail the company’s new anaemia pill, but should rival Fibrogen be celebrating?
